On Monday, Aclaris Therapeutics Inc (NASDAQ: ACRS) opened higher 8.84% from the last session, before settling in for the closing price of $2.15. Price fluctuations for ACRS have ranged from $1.05 to $5.17 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 15.24% over the last five years. Company’s average yearly earnings per share was noted 68.91% at the time writing. With a float of $92.30 million, this company’s outstanding shares have now reached $108.33 million.
Aclaris Therapeutics Inc (ACRS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Aclaris Therapeutics Inc is 14.80%, while institutional ownership is 73.48%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares.
Aclaris Therapeutics Inc (ACRS) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.11 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.01) by -0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.91% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.28% during the next five years compared to 15.24% growth over the previous five years of trading.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Check out the current performance indicators for Aclaris Therapeutics Inc (ACRS). In the past quarter, the stock posted a quick ratio of 3.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.37, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.59 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Analysing the last 5-days average volume posted by the [Aclaris Therapeutics Inc, ACRS], we can find that recorded value of 2.0 million was better than the volume posted last year of 1.0 million. As of the previous 9 days, the stock’s Stochastic %D was 65.26%.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 85.47%, which indicates a significant increase from 77.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.18 in the past 14 days, which was higher than the 0.11 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.95, while its 200-day Moving Average is $1.74. Now, the first resistance to watch is $2.44. This is followed by the second major resistance level at $2.53. The third major resistance level sits at $2.68. If the price goes on to break the first support level at $2.20, it is likely to go to the next support level at $2.05. Should the price break the second support level, the third support level stands at $1.96.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
There are currently 108,332K shares outstanding in the company with a market cap of 253.50 million. Presently, the company’s annual sales total 18,720 K according to its annual income of -132,070 K. Last quarter, the company’s sales amounted to 1,780 K and its income totaled -15,430 K.
